|
|
|
| London, United Kingdom Risk
and Pricing Analytics: Addressing Valuation Challenges in OTC and Structured
Products
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Executive Summary | 3 | |
| Introduction | 5 | |
| Market Developments and Trends | 6 | |
| OTC Derivatives | 6 | |
| Financial Innovation and Complex Instruments | 8 | |
| Regulatory Demands | 12 | |
| Business and Technology Considerations | 13 | |
| Implementation 'Routes to Market' | 13 | |
| Segments and Characteristics | 14 | |
| Challenge of Pricing and Risk Analytics | 16 | |
| Selected Pricing & Risk Analytics Software Vendors | 18 | |
| Celent's ABCD Vendor Analysis Framework | 18 | |
| Criteria for Inclusion | 18 | |
| Vendor Overview | 19 | |
| Solution Technology Overview | 21 | |
| Pricing | 23 | |
| Implementation Routes-to-Market/Approaches | 26 | |
| Coverage in Institution's Product Lifecycle | 27 | |
| Asset Class and Vendor 'Sweet Spots' | 28 | |
| Partnerships | 29 | |
| Vendor Strengths and Weaknesses | 30 | |
| Celent ABCD Vendor View | 34 | |
| Solution Selection & Implementation Considerations | 36 | |
| Lessons - Managing Pricing and Valuation Risks | 38 | |
| Conclusions/Looking Forward | 41 | |
| Appendix | 42 | |
| Objectivity and Methodology | 44 | |
| About Celent | 45 | |
